Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma

被引:0
|
作者
dos Santos, Margarida Varela [1 ,5 ]
Holth, Arild [1 ]
Lindemann, Kristina [2 ,3 ]
Staff, Anne Cathrine [2 ,4 ]
Davidson, Ben [1 ,2 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, N-0310 Oslo, Norway
[4] Oslo Univ Hosp, Ulleval Hosp, Dept Obstet & Gynecol, N-0450 Oslo, Norway
[5] Ctr Hospitalar Univ Lisboa Cent EPE, Serv Anat Patol, Rua Jose Antonio Serrano, P-1150199 Lisbon, Portugal
关键词
L1CAM; Immunohistochemistry; High-grade serous carcinoma; Effusion; Chemoresistance; Survival; OVARIAN-CANCER; L1; PROGRESSION; DIAGNOSIS; CELLS; CD171;
D O I
10.1016/j.ygyno.2023.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To analyze the expression and prognostic role of L1CAM in tubo-ovarian high-grade serous carci-noma (HGSC).Methods. L1CAM protein expression by immunohistochemistry was analyzed in 644 HGSC (413 effusions, 231 surgical specimens). Expression was analyzed for association with clinicopathologic parameters and survival.Results. L1CAM protein expression was found in 401/413 (97%) effusions and 209/231 (90%) surgical speci-mens, with significantly higher staining extent in effusions (p < 0.001). L1CAM protein expression in effusions was unrelated to clinicopathologic parameters (p > 0.05). In surgical specimens, higher L1CAM expression was significantly related to primary (intrinsic) chemoresistance (p = 0.017). High (>25%) L1CAM expression in HGSC effusions (p = 0.02), older patient age (p = 0.013), FIGO stage IV disease (p < 0.001) and larger residual disease volume (p = 0.001) were significantly associated with shorter overall survival (OS) in univariate analysis. In Cox multivariate analysis, only FIGO stage (p = 0.001) and residual disease volume (p = 0.003) were indepen-dent prognosticators of OS. L1CAM expression in effusions was unrelated to progression-free survival (PFS). There was no association between L1CAM expression in surgical specimens and survival.Conclusion. L1CAM is overexpressed in HGSC effusions compared to surgical specimens. Its overexpression in effusions is significantly associated with shorter OS, but not independently of established prognostic factors such as FIGO stage and residual disease volume.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:76 / 81
页数:6
相关论文
共 50 条
  • [21] Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
    Hollis, Robert L.
    Croy, Ian
    Churchman, Michael
    Bartos, Clare
    Rye, Tzyvia
    Gourley, Charlie
    Herrington, C. Simon
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1034 - 1042
  • [22] Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
    Robert L. Hollis
    Ian Croy
    Michael Churchman
    Clare Bartos
    Tzyvia Rye
    Charlie Gourley
    C. Simon Herrington
    British Journal of Cancer, 2022, 127 : 1034 - 1042
  • [23] Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles
    Magrill, Jamie
    Karnezis, Anthony N.
    Tessier-Cloutier, Basile
    Talhouk, Aline
    Kommoss, Stefan
    Cochrane, Dawn
    Chow, Christine
    Cheng, Angela
    Soslow, Robert
    Hauptmann, Steffen
    du Bois, Andreas
    Pfisterer, Jacobus
    Gilks, C. Blake
    Huntsman, David G.
    Kommoss, Friedrich
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (06) : 552 - 561
  • [24] Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma
    Tessier-Cloutier, Basile
    Cochrane, Dawn R.
    Karnezis, Anthony N.
    Colborne, Shane
    Magrill, Jamie
    Talhouk, Aline
    Zhang, Jonathan
    Leung, Samuel
    Hughes, Christopher S.
    Piskorz, Anna
    Cheng, Angela S.
    Greening, Kendall
    du Bois, Andreas
    Pfisterer, Jacobus
    Soslow, Robert A.
    Kommoss, Stefan
    Brenton, James D.
    Morin, Gregg B.
    Gilks, C. Blake
    Huntsman, David G.
    Kommoss, Friedrich
    HUMAN PATHOLOGY, 2020, 101 : 40 - 52
  • [25] Intralymphatic Histiocytosis Associated With Tubo-ovarian High-grade Serous Carcinoma: Case Report and Review of the Literature
    Bonometti, Arturo
    Carbone, Riccardo
    Cassani, Chiara
    Dioli, Claudia
    Lucato, Elena
    Spinillo, Arsenio
    Paulli, Marco
    Cesari, Stefania
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (02) : 192 - 195
  • [26] Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
    Wang, Chen
    Block, Matthew S.
    Cunningham, Julie M.
    Sherman, Mark E.
    McCauley, Bryan M.
    Armasu, Sebastian M.
    Vierkant, Robert A.
    Traficante, Nadia
    Talhouk, Aline
    Doherty, Jennifer A.
    Pejovic, Nadja
    Kobel, Martin
    Jorgensen, Brooke D.
    Garsed, Dale W.
    Fereday, Sian
    Ramus, Susan J.
    Ariyaratne, Dinuka
    Anglesio, Michael S.
    Widschwendter, Martin
    Pejovic, Tanja
    Bosquet, Jesus Gonzalez
    Bowtell, David D.
    Winham, Stacey J.
    Goode, Ellen L.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (03) : 542 - 549
  • [27] Rare case of paraneoplastic cerebellar degeneration secondary to high-grade serous carcinoma of tubo-ovarian origin
    Butt, Eman
    Tadross, John A.
    Chadda, Karan R.
    Latimer, John
    BMJ CASE REPORTS, 2019, 12 (08)
  • [28] Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
    Ditzel, Helena M.
    Strickland, Kyle C.
    Meserve, Emily E.
    Stover, Elizabeth
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Muto, Michael G.
    Liu, Joyce F.
    Feltmate, Colleen
    Horowitz, Neil
    Berkowitz, Ross S.
    Gupta, Mamta
    Hecht, Jonathan L.
    Lin, Douglas I.
    Jochumsen, Kirsten M.
    Welch, William R.
    Hirsch, Michelle S.
    Quade, Bradley J.
    Lee, Kenneth R.
    Crum, Christopher P.
    Mutter, George L.
    Nucci, Marisa R.
    Howitt, Brooke E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2019, 38 (03) : 230 - 240
  • [29] The prognostic value of the chemotherapy response score in tubo-ovarian or primary peritoneal high-grade serous carcinoma
    Weirich, Larissa
    Bodinaku, Ina
    Bradford, Leslie
    Craig, Wendy
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S231 - S232
  • [30] BRCA1 and MAD2 Are Coexpressed and Are Prognostic Indicators in Tubo-ovarian High-Grade Serous Carcinoma
    Byrne, Tara
    Nelson, Laura
    Beirne, James P.
    Sharpe, Daniel
    Quinn, Jennifer E.
    McCluggage, W. Glenn
    Robson, Tracy
    Furlong, Fiona
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (03) : 472 - 478